WO2012102527A3 - 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도 - Google Patents

조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도 Download PDF

Info

Publication number
WO2012102527A3
WO2012102527A3 PCT/KR2012/000532 KR2012000532W WO2012102527A3 WO 2012102527 A3 WO2012102527 A3 WO 2012102527A3 KR 2012000532 W KR2012000532 W KR 2012000532W WO 2012102527 A3 WO2012102527 A3 WO 2012102527A3
Authority
WO
WIPO (PCT)
Prior art keywords
surface protein
regulatory
cell
specific surface
novel use
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2012/000532
Other languages
English (en)
French (fr)
Other versions
WO2012102527A2 (ko
Inventor
이상규
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US14/427,421 priority Critical patent/US11655287B2/en
Publication of WO2012102527A2 publication Critical patent/WO2012102527A2/ko
Publication of WO2012102527A3 publication Critical patent/WO2012102527A3/ko
Anticipated expiration legal-status Critical
Priority to US16/233,738 priority patent/US11091538B2/en
Priority to US16/591,023 priority patent/US20200048335A1/en
Priority to US17/374,224 priority patent/US11932686B2/en
Priority to US17/575,039 priority patent/US20220135662A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5302—Apparatus specially adapted for immunological test procedures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9493—Immunosupressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

본 발명은 조절자 T 세포에 특이적으로 존재하는 표면단백질 Lrig-1의 새로운 용도에 관한 것이다. 보다 자세하게는 표면단백질 Lrig-1의 발현을 억제하는 siRNA를 포함하는 면역억제제에 관한 것이다. 또한, Lrig1의 단백질 또는 이 단백질을 코딩하는 유전자를 억제하는 면역억제제를 스크리닝하는 방법에 관한 것이다. 이를 통하여, 부작용이 적고 특이성이 높은 면역억제제를 개발할 수 있다.
PCT/KR2012/000532 2011-01-24 2012-01-20 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도 Ceased WO2012102527A2 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US14/427,421 US11655287B2 (en) 2011-01-24 2012-01-20 Use of regulatory T cell-specific surface protein LRIG-1
US16/233,738 US11091538B2 (en) 2011-01-24 2018-12-27 Use of regulatory T cell-specific surface protein LRIG-1
US16/591,023 US20200048335A1 (en) 2011-01-24 2019-10-02 Novel use of regulatory t cell-specific surface protein lrig-1
US17/374,224 US11932686B2 (en) 2011-01-24 2021-07-13 Use of regulatory T cell-specific surface protein LRIG-1
US17/575,039 US20220135662A1 (en) 2011-01-24 2022-01-13 Novel use of regulatory t cell-specific surface protein lrig-1

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110007022A KR101847523B1 (ko) 2011-01-24 2011-01-24 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도
KR10-2011-0007022 2011-01-24

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US14/427,421 A-371-Of-International US11655287B2 (en) 2011-01-24 2012-01-20 Use of regulatory T cell-specific surface protein LRIG-1
US16/233,738 Continuation US11091538B2 (en) 2011-01-24 2018-12-27 Use of regulatory T cell-specific surface protein LRIG-1
US16/591,023 Division US20200048335A1 (en) 2011-01-24 2019-10-02 Novel use of regulatory t cell-specific surface protein lrig-1

Publications (2)

Publication Number Publication Date
WO2012102527A2 WO2012102527A2 (ko) 2012-08-02
WO2012102527A3 true WO2012102527A3 (ko) 2012-12-20

Family

ID=46581267

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/000532 Ceased WO2012102527A2 (ko) 2011-01-24 2012-01-20 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도

Country Status (3)

Country Link
US (5) US11655287B2 (ko)
KR (1) KR101847523B1 (ko)
WO (1) WO2012102527A2 (ko)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101847523B1 (ko) * 2011-01-24 2018-05-28 연세대학교 산학협력단 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도
EP3613772A4 (en) 2017-04-18 2020-12-30 Good T Cells, Inc. SPECIFIC BINDING MOLECULE FOR LRIG-1 PROTEIN AND ITS USE
EP3755350A4 (en) * 2018-02-23 2021-11-03 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF VISTA AND HIS ASSOCIATION PARTNER
EP3792276A4 (en) * 2018-04-26 2022-02-16 Good T Cells, Inc. NOVEL FUSION PROTEIN AND PHARMACEUTICAL COMPOSITION TO PREVENT OR TREAT CANCER THEREOF
US20210363244A1 (en) * 2018-05-09 2021-11-25 Good T Cells, Inc. Epitope of Regulatory T Cell surface Antigen and Antibody Specifically Biding Thereto
CN112543644A (zh) * 2018-07-24 2021-03-23 古德T细胞有限公司 一种预防和治疗免疫相关疾病的组合物
US20220275081A1 (en) * 2018-10-17 2022-09-01 Good T Cells, Inc. Binding molecule specific for lrig-1 protein and use thereof
KR20200112745A (ko) * 2019-03-20 2020-10-05 주식회사 굳티셀 뇌신경계 질환의 예방 또는 치료용 조성물
WO2021006714A1 (ko) * 2019-07-11 2021-01-14 주식회사 굳티셀 면역체크포인트 억제제 저항성 암의 예방, 개선 또는 치료용 조성물
US20220281973A1 (en) * 2019-08-29 2022-09-08 Truebinding, Inc. Antibodies and blocking the interaction of vista and its binding partner
CA3156600A1 (en) * 2019-11-08 2021-05-14 Jung Ho Kim Epitope of regulatory t cell surface antigen, and antibody specifically binding thereto
KR102694121B1 (ko) * 2020-10-22 2024-08-13 주식회사 굳티셀 활성화된 면역 세포의 세포 표면 항원 및 이의 다양한 용도
KR20240115192A (ko) * 2023-01-17 2024-07-25 주식회사 굳티셀 조절 t 세포 표면 항원 및 이에 특이적으로 결합하는 항체
CN120882739A (zh) * 2023-03-10 2025-10-31 古德T细胞有限公司 调节性t细胞表面抗原的表位，以及特异性结合该表位的抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1930415A1 (en) * 2005-09-30 2008-06-11 Kyoto University Development of method for screening of compound capable of improving the production of regulatory t cell, and method for production of regulatory t cell using immunosuppressive macrolide antibiotic

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048587A1 (en) * 2003-07-17 2005-03-03 Tolerrx, Inc. Methods for identifying tolerance modulatory compounds and uses therefor
EP1752536A4 (en) 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
EP1799262A4 (en) * 2004-10-15 2009-10-21 Seattle Genetics Inc ANTI-CD70 ANTIBODIES AND ITS USE FOR THE TREATMENT AND PREVENTION OF CANCER DISORDERS AND IMMUNE DISORDERS
US20060204503A1 (en) 2005-01-31 2006-09-14 Biogen Idec Ma Inc. Treatment of cancer using antibodies to polypeptides differentially expressed in human lung tumors
WO2006127152A2 (en) * 2005-04-05 2006-11-30 University Of Southern California Methods for making and using regulatory t cells
US8951793B2 (en) 2008-08-21 2015-02-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of making an isolated population of FOXP3+ regulatory T cells
EP2408934B1 (en) 2009-03-18 2014-11-12 Adelaide Research & Innovation Pty Ltd. Peptidase inhibitor 16 (pi16) as a biomarker for regulatory t (treg) cells and uses thereof
CN101603030B (zh) * 2009-07-14 2011-05-25 吕凌 一种体外扩增调节性t细胞的方法
AU2011325956B2 (en) 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
KR101847523B1 (ko) * 2011-01-24 2018-05-28 연세대학교 산학협력단 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1930415A1 (en) * 2005-09-30 2008-06-11 Kyoto University Development of method for screening of compound capable of improving the production of regulatory t cell, and method for production of regulatory t cell using immunosuppressive macrolide antibiotic

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAI M ET AL., CANCER LETT, vol. 278, no. 1, 8 June 2009 (2009-06-08), pages 104 - 112 *
GUO D ET AL., ACTA NEUROPATHOL, MARCH, vol. 111, no. 3, 2006, pages 238 - 246 *
WEI-MIN YANG ET AL., BJU INT, vol. 98, no. 4, October 2006 (2006-10-01), pages 898 - 902 *

Also Published As

Publication number Publication date
US11932686B2 (en) 2024-03-19
US11655287B2 (en) 2023-05-23
KR20120085593A (ko) 2012-08-01
WO2012102527A2 (ko) 2012-08-02
US20220135662A1 (en) 2022-05-05
US20190185552A1 (en) 2019-06-20
KR101847523B1 (ko) 2018-05-28
US20150239964A1 (en) 2015-08-27
US20210340235A1 (en) 2021-11-04
US20200048335A1 (en) 2020-02-13
US11091538B2 (en) 2021-08-17

Similar Documents

Publication Publication Date Title
WO2012009644A3 (en) Methods to identify synthetic and natural rna elements that enhance protein translation
WO2012072096A8 (en) Method for cellular rna expression
WO2013006544A8 (en) Methods for making multimeric polypeptides
MX2014003979A (es) Nucleosidos, nucleotidos, y acidos nucleicos modificados, y usos de los mismos.
WO2011079902A3 (en) Biological inhibitors of ror1 capable of inducing cell death
MX2010008099A (es) Anticuerpos y angiopoyetina-2 estabilizados y sus usos.
UA116092C2 (uk) Спосіб та композиція для боротьби з бур'янами (варіанти)
MY162323A (en) Anticoagulant antidotes
WO2011156654A3 (en) Pathways characterization of cells
WO2014144942A3 (en) Dnai for the modulation of genes
NZ704718A (en) Epcam aptamer for detection of cancer stem cells
WO2012096461A3 (ko) 줄기세포의 부유배양용 조성물
NZ704719A (en) Cd133 aptamers for detection of cancer stem cells
WO2013188469A3 (en) Pathways characterization of cells
IN2015KN00073A (ko)
MX349801B (es) Sustratos de enzimas de ácido nucleico.
WO2012103355A3 (en) Methods of detecting lung cancer
WO2013152860A3 (en) Improved antibody light chains
TN2013000388A1 (en) Anticoagulant antidotes
WO2014145870A3 (en) Novel compositions, methods and kits for blood typing
WO2013053857A3 (en) Gene cluster for biosynthesis of griselimycin and methylgriselimycin
WO2012175745A9 (en) Cell secreted proteins for the treatment of myocardial infarction
WO2013096683A3 (en) Enhanced production of isoprene using marine bacterial cells
MX2014004735A (es) Adicion de hierro para mejorar cultivo celular.
MX2013008103A (es) Purificacion de inhibidor de proteasa alfa1 derivado de cultivo celular.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12739603

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 29/11/2013)

122 Ep: pct application non-entry in european phase

Ref document number: 12739603

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14427421

Country of ref document: US